Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharvaris NV PHVS

Healthcare Biotechnology
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Recent & Breaking News (NDAQ:PHVS)

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

GlobeNewswire March 5, 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

GlobeNewswire February 22, 2024

Pharvaris Announces Extraordinary Meeting of Shareholders

GlobeNewswire February 16, 2024

Pharvaris to Present at the WSAAI Annual Meeting 2024

GlobeNewswire January 26, 2024

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

GlobeNewswire January 22, 2024

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

GlobeNewswire January 5, 2024

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

GlobeNewswire December 8, 2023

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

GlobeNewswire December 6, 2023

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

GlobeNewswire December 6, 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

GlobeNewswire November 30, 2023

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

GlobeNewswire November 15, 2023

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

GlobeNewswire November 9, 2023

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 2, 2023

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

GlobeNewswire October 30, 2023

Pharvaris To Present at the APAAACI 2023 International Conference

GlobeNewswire October 13, 2023

Pharvaris To Present at the CIIC Fall 2023 Conference

GlobeNewswire October 4, 2023

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 19, 2023

Pharvaris To Present at the 18th German Allergy Congress

GlobeNewswire September 6, 2023

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 6, 2023

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

GlobeNewswire August 23, 2023